RJF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Raymond James Financial Inc (RJF) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. The technical indicators are bearish, options data suggests cautious sentiment, and financial performance shows declining net income and EPS. While there are no significant positive catalysts or recent influential trades, the stock's long-term growth potential is acknowledged by analysts. However, current market conditions and trends do not provide a compelling entry point.
The stock is currently in a bearish trend. The MACD is negatively expanding with a histogram of -0.2, RSI is neutral at 35.287, and moving averages indicate a bearish alignment (SMA_200 > SMA_20 > SMA_5). The price is trading near the S1 support level of 151.323, with resistance levels at 155.422 and 159.521. The stock has a 70% chance of declining by -0.82% in the next day and -4.79% in the next month.
Barclays initiated coverage with an Overweight rating and a $191 price target, citing long-term growth potential and attractive valuation. Gross margin increased by 2.06% YoY, reflecting operational efficiency.
Recent financials show a decline in net income (-6.19% YoY) and EPS (-2.45% YoY), indicating profitability challenges. Analysts have mixed ratings, with some lowering price targets due to concerns over slowing growth and margin opportunities. The stock is also underperforming in the short term, with a bearish technical setup.
In Q1 2026, revenue increased by 3.27% YoY to $4.078 billion, but net income dropped by 6.19% YoY to $561 million. EPS decreased by 2.45% YoY to 2.79. Gross margin improved slightly to 89.19, up 2.06% YoY, indicating some operational strength despite declining profitability.
Analyst sentiment is mixed. Barclays is bullish with an Overweight rating and a $191 price target, citing long-term growth potential. However, TD Cowen lowered its price target to $181, citing mixed views on growth and margins. BofA raised its target to $198 but maintained a Neutral rating. Overall, analysts acknowledge the company's growth potential but highlight near-term headwinds and valuation concerns.
